https://doi.org/10.4081/monaldi.2024.3128
Impact of the COVID-19 pandemic on the clinical features of patients with chronic obstructive pulmonary disease: an observational cross-sectional study
Submitted: July 8, 2024
Accepted: September 24, 2024
Published: November 20, 2024
Accepted: September 24, 2024
Abstract Views: 807
PDF_EARLY VIEW: 152
SUPPLEMENTARY MATERIAL: 17
SUPPLEMENTARY MATERIAL: 17
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The presence of chronic obstructive pulmonary disease (COPD) and COVID-19 infection is a detrimental combination for patients and can cause negative clinical consequences. The investigation aimed to compare sociodemographic and clinical parameters of COPD individuals hospitalized for exacerbations before and at the end of the COVID-19 pandemic. An observational cross-sectional study including 222 patients with COPD was conducted in two stages: a survey and assessment of clinical and laboratory data of patients hospitalized from September 2022 to March 2023 (n=98) and processing of the medical histories of patients with COPD who received hospital treatment in 2017 and 2018 (n=124). A comparative analysis of patients who received inpatient treatment for COPD showed that the frequency of patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) I was half as high after the COVID-19 pandemic, whereas the individuals with GOLD IV were more frequent during the same period (p<0.05). Multiple regression analysis proved the effects of smoking status and previous COVID-19 infection on the health status of patients with COPD according to COPD Assessment Test data (p<0.05). There was an increase in the frequency of comorbid pathologies in the post-COVID period: hypertension, coronary heart disease, gastrointestinal diseases, anemia (p<0.05), and other diseases. This study highlights the significant influence of the COVID-19 infection on people with COPD, which manifested as impaired lung function and an increased incidence of comorbidities.
Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Resp Med 2022;10:447-58.
DOI: https://doi.org/10.1016/S2213-2600(21)00511-7
WHO. Chronic obstructive pulmonary disease (COPD). 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019. BMJ 2022;378:e069679.
DOI: https://doi.org/10.1136/bmj-2021-069679
Gulis G, Aringazina A, Sangilbayeva Z, et al. Population health status of the Republic of Kazakhstan: Trends and implications for public health policy. Int J Env Res Publ Health 2021;18:12235.
DOI: https://doi.org/10.3390/ijerph182212235
Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. New Eng J Med 2019;381:1248-56.
DOI: https://doi.org/10.1056/NEJMra1900475
Kochnieva O, Kotsar O. The role of microbial biofilms in the development of respiratory system complications in patients with COVID-19: a literature review. Bull Biol Res 2023;5:40-6.
DOI: https://doi.org/10.61751/bmbr.2706-6290.2023.3.40
Anzueto A. Impact of exacerbations on COPD. Eur Resp Rev 2010;19:113-8.
DOI: https://doi.org/10.1183/09059180.00002610
Oliynyk OV, Rorat M, Solyarik SO, et al. Impact of alteplase on mortality in critically ill patients with COVID-19 and pulmonary embolism. Virus 2023;15:1513.
DOI: https://doi.org/10.3390/v15071513
Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. Resp Res 2020;21:77.
DOI: https://doi.org/10.1186/s12931-020-01340-0
Hewitt R, Farne H, Ritchie A, et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Therap Adv Resp Dis 2016;10:158-74.
DOI: https://doi.org/10.1177/1753465815618113
Ning Q, Wu D, Wang X, et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Sign Transduct Targ Therap 2022;7:57.
DOI: https://doi.org/10.1038/s41392-022-00907-1
Quintero DR, Collazos NE, García AM, et al. Effectiveness of respiratory muscle training in pulmonary rehabilitation programs in patients with Sarcoidosis. A scoping review. Gac Med Carac 2023;131:132-41.
Fließer E, Birnhuber A, Marsh LM, et al. Dysbalance of ACE2 levels – a possible cause for severe COVID-19 outcome in COPD. J Pathol Clin Res 2021;7:446-58.
DOI: https://doi.org/10.1002/cjp2.224
Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: Interrelationships. Curr Opin Pulm Med 2022;28:76-83.
DOI: https://doi.org/10.1097/MCP.0000000000000834
Dmytriiev D, Dobrovanov O. Post-COVID pain syndrome. Anaesth Pain Intens Care 2021;25:505-12.
DOI: https://doi.org/10.35975/apic.v25i4.1582
Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immun 2020;11:827.
DOI: https://doi.org/10.3389/fimmu.2020.00827
Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020;15:e0233147.
DOI: https://doi.org/10.1371/journal.pone.0233147
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Eng J Med 2020;382:1708-20.
DOI: https://doi.org/10.1056/NEJMoa2002032
Kalyanaraman Marcello R, Dolle J, Grami S, et al. Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS One 2020;15:e0243027.
DOI: https://doi.org/10.1371/journal.pone.0243027
Stridsman C, Vanfleteren L, Konradsen JR, et al. Predictors of severe COVID-19 in a registry-based Swedish cohort of patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2021;58:2101920.
DOI: https://doi.org/10.1183/13993003.01920-2021
Lutter JI, Jörres RA, Welte T, et al. Impact of education on COPD severity and all-cause mortality in lifetime never-smokers and longtime ex-smokers: results of the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis 2020;15:2787-98.
DOI: https://doi.org/10.2147/COPD.S273839
Meza D, Khuder B, Bailey JI, et al. Mortality from COVID-19 in patients with COPD: a US study in the N3C Data Enclave. Int J Chron Obstr Pulmon Dis 2021;16:2323-6.
DOI: https://doi.org/10.2147/COPD.S318000
Huang BZ, Chen Z, Sidell MA, et al. Asthma disease status, COPD, and COVID-19 severity in a large multiethnic population. J Allerg Clin Immun Pract 2021;9:3621-8.e2.
DOI: https://doi.org/10.1016/j.jaip.2021.07.030
Gunawan VA, Triyono EA. COVID-19, a self-limiting disease – a case report of a severe COVID-19 pneumonia patient with multiple comorbidities successfully treated without antivirals. Gac Med Carac 2024;132:182-6.
DOI: https://doi.org/10.47307/GMC.2024.132.1.18
Parisi GF, Indolfi C, Decimo F, et al. COVID-19 Pneumonia in children: from etiology to management. Front Pediat 2020;8:616622.
DOI: https://doi.org/10.3389/fped.2020.616622
McIntosh K. COVID-19: epidemiology, virology, and prevention. 2024. Available from: https://www.uptodate.com/contents/covid-19-epidemiology-virology-and-prevention#H4014462337.
Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 2020;396:313-9.
DOI: https://doi.org/10.1016/S0140-6736(20)31304-0
Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March23-May 12, 2020. JAMA Intern Med 2020;180:1576-86.
DOI: https://doi.org/10.1001/jamainternmed.2020.4130
Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Resp Res 2014;15:122.
DOI: https://doi.org/10.1186/PREACCEPT-1114873655135960
Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Resp Res 2017;18:67.
DOI: https://doi.org/10.1186/s12931-017-0548-3
Müllerova H, Maselli DG, Locantore N, et al. Hospitalized exacerbations of COPD: Risk factors and outcomes in the ECLIPSE cohort. Chest 2015;147:999-1007.
DOI: https://doi.org/10.1378/chest.14-0655
Alfageme I, Reyes N, Merino M, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron Resp Dis 2010;7:135-45.
DOI: https://doi.org/10.1177/1479972310368692
Yessentayeva SY, Makarov VA, Kalmatayeva ZA, et al. Molecular genetic tests in survival factors in patients with NSCLC in the clinical practice of Kazakhstan. Med J Islam Rep Iran 2021;35:133.
DOI: https://doi.org/10.47176/mjiri.35.133
Song Q, Zhao YY, Zeng YQ, et al. The characteristics of airflow limitation and future exacerbations in different GOLD groups of COPD patients. Int J Chron Obstr Pulmon Dis 2021;16:1401-12.
DOI: https://doi.org/10.2147/COPD.S309267
Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. New Eng J Med 2011;365:1184-92.
DOI: https://doi.org/10.1056/NEJMoa1105482
Xiong H, Huang Q, Shuai T, et al. Assessment of comorbidities and prognosis in patients with COPD diagnosed with the fixed ratio and the lower limit of normal: a systematic review and meta-analysis. Resp Res 2020;21:189.
DOI: https://doi.org/10.1186/s12931-020-01450-9
Wytrychiewicz K, Pankowski D, Janowski K, et al. Smoking status, body mass index, health-related quality of life, and acceptance of life with illness in stable outpatients with COPD. Front Psych 2019;10:1526.
DOI: https://doi.org/10.3389/fpsyg.2019.01526
Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword. Circulation 2020;142:426-8.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.047049
Tadic M, Cuspidi C, Grassi G, et al. COVID‐19 and arterial hypertension: hypothesis or evidence? J Clin Hypert 2020;22:1120-6.
DOI: https://doi.org/10.1111/jch.13925
Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364-74.
DOI: https://doi.org/10.1007/s11427-020-1643-8
Kamkhen VB, Mamyrbekova SA, Daniyarova AB, et al. Specifics of the mental component of the quality of life of almaty doctors in the context of the COVID-19 pandemic. Phys Activ Health 2022;6:201-7.
DOI: https://doi.org/10.5334/paah.200
Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circul Res 2020;126:1456-74.
DOI: https://doi.org/10.1161/CIRCRESAHA.120.317015
Nuritdinov N, Kamilova U. Left ventricular diastolic function in the patients with chronic heart failure. J Amer Coll Cardiol 2018;72:C167.
DOI: https://doi.org/10.1016/j.jacc.2018.08.748
Esposito L, Cancro FP, Silverio A, et al. COVID-19 and acute coronary syndromes: From pathophysiology to clinical perspectives. Oxidat Med Cellul Longev 2021;2021:4936571.
DOI: https://doi.org/10.1155/2021/4936571
Canale MP, Menghini R, Martelli E, et al. COVID-19-associated endothelial dysfunction and microvascular injury: from pathophysiology to clinical manifestations. Card Electrophys Clin 2022;14:21-8.
DOI: https://doi.org/10.1016/j.ccep.2021.10.003
Bartoszewicz M, Czaban SL, Bartoszewicz K, et al. Bacterial bloodstream infection in critically ill patients with COVID-19: a retrospective cohort study. Therap Adv Infect Dis 2023;10:20499361231207178.
DOI: https://doi.org/10.1177/20499361231207178
SeyedAlinaghi S, Karimi A, Mirzapour P, et al. The relationship between C-reactive protein and levels of various cytokines in patients with COVID-19: a systematic review and correlation analysis. Health Sci Rep 2022;5:e868. Retraction in: Health Sci Rep 2023;6:e1459.
DOI: https://doi.org/10.1002/hsr2.868
Noels H, Weber C, Koenen RR. Chemokines as therapeutic targets in cardiovascular disease. Arterioscl Thromb Vascul Biol 2019;39:583-92.
DOI: https://doi.org/10.1161/ATVBAHA.118.312037
Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hemat 2007;14:55-61.
DOI: https://doi.org/10.1097/00062752-200701000-00011
Kane SV. COVID-19: issues related to gastrointestinal disease in adults. 2023. Available from: https://www.uptodate.com/contents/covid-19-issues-related-to-gastrointestinal-disease-in-adults/print.
Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Natur Commun 2023;14:983.
DOI: https://doi.org/10.1038/s41467-023-36223-7
Ethics Approval
This research has been accorded with all ethic committee demands of the Al-Farabi Kazakh National University (protocol No. IRB-A403. IRB00010790 Al-Farabi Kazakh National University (IRB#1).How to Cite
Kurmanova, Gaukhar, Almas Zhanaev, Akzharkyn Kaldybek, Balkiya Abdrakhmanova, and Almira Akparova. 2024. “Impact of the COVID-19 Pandemic on the Clinical Features of Patients With Chronic Obstructive Pulmonary Disease: An Observational Cross-Sectional Study”. Monaldi Archives for Chest Disease, November. https://doi.org/10.4081/monaldi.2024.3128.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
